James Andrea S. 4

What Happened

• James Andrea S., Chief Financial Officer of Insight Molecular Diagnostics (IMDX), had 28,302 restricted stock units (RSUs convert to common shares) vest on March 26, 2026. Of those, 11,298 shares were withheld by the company to cover required tax withholding (reported at $4.11/share, totaling $46,435). The filing indicates no sale of shares — this was a vesting/tax-withholding event, not a market sale.

Key Details

• Transaction date: March 26, 2026; Form 4 filed March 30, 2026 (timely within two business days).
• Shares converted/issued on vesting: 28,302 RSUs -> 28,302 shares.
• Shares withheld for taxes: 11,298 shares at $4.11/share = $46,435 withheld (reported as code F).
• Reporting person did not sell any shares (footnote F2).
• Footnotes: RSUs were granted under the 2018 Equity Incentive Plan; each RSU equals one share. 25% of the grant vested on 3/26/2026; the remaining 75% vests in equal installments on each of the 2nd–4th anniversaries, subject to continued service (footnotes F1, F3).
• Shares owned after the transaction: not specified in the excerpt of the filing.

Context

• This was a routine RSU vesting with share-withholding to satisfy tax obligations (common practice), not a cash sale. Although the Form 4 shows "exercise/conversion" entries, the footnotes clarify these were RSUs settling into shares rather than an options-for-cash sale. Vesting events are standard compensation realizations and do not by themselves indicate an insider buying or selling for investment reasons.